NCT01381861: Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma |
|
|
| Completed | 2 | 23 | US | Carotuximab (TRC105), TRC105, NSC#754227 | Tracon Pharmaceuticals Inc. | Recurrent Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma | 08/12 | 12/13 | | |
NCT01328574: TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma |
|
|
| Completed | 2 | 13 | US | TRC105 | National Cancer Institute (NCI) | Urothelial Carcinoma, Ureteral Neoplasms, Ureter Cancer, Neoplasm, Ureteral, Cancer of the Ureter | 05/14 | 11/14 | | |
NCT01727089: Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer |
|
|
| Completed | 2 | 59 | US, RoW | Anti-Endoglin Chimeric Monoclonal Antibody TRC105, TRC105, Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Laboratory Biomarker Analysis, Pharmacological Study | National Cancer Institute (NCI) | Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma | 08/17 | 08/17 | | |
NCT01090765: A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC) |
|
|
| Completed | 1/2 | 21 | US | TRC105 | National Cancer Institute (NCI) | Prostate Cancer, Metastatic Castrate Resistant Prostate Cancer | 04/14 | 04/15 | | |
